Pharmaceutical

ESMO 2024: Enhertu to eclipse SOC for HER2+ breast cancer with brain metastases

GlobalData forecasts predict Enhertu will retain its dominant market position in the ADC treatment landscape.

Sep 16, 2024 - 04:00
ESMO 2024: Enhertu to eclipse SOC for HER2+ breast cancer with brain metastases
GlobalData forecasts predict Enhertu will retain its dominant market position in the ADC treatment landscape.
Read the original article

Tags:

Previous Article

ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC

Next Article

Express Scripts sues FTC and demands drug pricing report retraction

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Genentech review of Tessier-Lavigne paper finds no evidence of fraud — but hints at a different misconduct case

Genentech review of Tessier-Lavigne paper finds no evid...

Apr 7, 2023

Pharma M&A: The top high value deals in 2023

Pharma M&A: The top high value deals in 2023

Jun 26, 2024

FDA grants priority review for Daiichi Sankyo-AstraZeneca’s Enhertu

FDA grants priority review for Daiichi Sankyo-AstraZene...

Jan 29, 2024